CXCL9 and colorectal cancer: In addition, treatment of colorectal cancer patients by murlentamab was associated with an increase in CXCL9 and CXCL10 blood levels, two interferon-inducible chemokines described as critical immune modulators and survival predictors in colorectal cancer [39], in 13 patients out of 16 and 9 patients out of 15, respectively (Figure 1C).